Shanghai Henlius Biotech, Inc. (HKG:2696)
Hong Kong · Delayed Price · Currency is HKD 78.15
+2.95 (3.92%)
May 7, 2026, 4:08 PM HKT
Shanghai Henlius Biotech Earnings Call Transcripts
Fiscal Year 2026
-
The session detailed a robust global clinical pipeline, with multiple late-stage assets showing strong efficacy and safety, and several regulatory filings and data readouts expected in 2024. Strategic focus includes next-gen IO, ADCs, and global expansion, with funding from biosimilar sales and partnerships.